“Optimizing Outcomes in Ovarian Cancer using Personalized Medicine” is a collaborative educational project of The Society of Gynecologic Oncology (SGO) and the Association of Community Cancer Centers (ACCC), supported by an independent medical education grant from AstraZeneca and Merck.

Together, SGO and ACCC have created unique tools aimed at enhancing the delivery of personalized medicine in a community setting. The Chemotherapy &Targeted Therapy Subcommittee of the SGO Education Committee previously developed flash cards that highlight therapies which may be used less frequently and offer a “refresher” on dosing, side effects, contraindications, and more. This current batch of flash cards expands on this project and provides up-to-date information on some key drug options for patients with ovarian cancer. 

Included in this resource are individual PDFs on the following:

• Niraparib
• Olaparib
• Pemetrexed
• Rucaparib
• Sorafenib
• Trametinib